Breaking Finance News

A statement released earlier today by Stifel about CoLucid Pharmaceuticals (NASDAQ:CLCD) bumps the target price to $30.00

Stifel upped the estimated target of CoLucid Pharmaceuticals (NASDAQ:CLCD) to $30, indicating a possible upside of 0.07%.

Having a price of $28.13, CoLucid Pharmaceuticals (NASDAQ:CLCD) traded 5.28% higher on the day. The last stock price is up 249.74% relative to the 200-day average, compared with the S&P 500 which has decreased -0.01% over the same period. The company has registered a 50-day moving average of $11.13 and two hundred day average of $8.04. 1,135,619 shares of CoLucid Pharmaceuticals exchanged hands, up from ann average volume of 429,398

Recent Performance Graph:

CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals has a one-year low of $3.57 and a one-year high of $28.44. CLCD’s market cap is currently $0.0.

General Company Details For CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, and placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *